Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Exclusion criteria

• ✕. Platelet count \< 75 × 10\^9/L.
• ✕. Absolute neutrophil count \< 1.0 × 10\^9/L.
• ✕. Hemoglobin \< 9.0 g/dL (red blood cell transfusion and erythropoietin may be used to reach at least 9.0 g/dL, but must have been administered at least 2 weeks prior to the first dose of study drug.
• ✕. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 × the upper limit of normal (ULN) if no hepatic metastases are present; \> 5 × ULN if hepatic metastases are present.
• ✕. Total bilirubin \> 1.5 × ULN; \> 3 × ULN with direct bilirubin \> 1.5 × ULN in presence of Gilbert's disease.
• ✕. Estimated (Cockcroft-Gault formula) or measured creatinine clearance \< 40 mL/min.
• ✕. Total serum phosphorus \> 5.5 mg/dL